Results 51 to 60 of about 164 (107)

Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis

Physiological Reports, Volume 12, Issue 24, December 2024.
Abstract Multiple sclerosis (MS) is a chronic neurological condition resulting in decreased aerobic capacity (peak VO2). The hemodynamic responses to peak exercise in MS are unknown. Further, it is unknown if the hemodynamic responses are due to disease or fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease that disproportionately impacts Black people with MS (PwMS), who experience more severe disease and higher relapse rates compared with non-Black populations.
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Nicholas Belviso, Sai L. Shankar, Jason P. Mendoza, Boyang Bian, James B. Lewin, Kinyee Fong   +12 more
doaj   +1 more source

COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review

Health Science Reports, Volume 7, Issue 10, October 2024.
Abstract Background The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) initiated the COVID‐19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact.
Farhad Mahmoudi, Omid Mirmosayyeb, Elnaz Shaabani, Elham Moases Ghaffary, Flavia Nelson   +4 more
wiley   +1 more source

Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population

Annals of Clinical and Translational Neurology, Volume 11, Issue 6, Page 1526-1534, June 2024.
Abstract Objective Our objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease‐modifying therapy within this prevalent cohort.
Sue Kwon, Stefan Sillau, John R. Corboy, Kavita V. Nair, Aaron M. Carlson   +4 more
wiley   +1 more source

Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decreases ISR activation in DRG neurons

, 2023
Abstract Diabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes mechanical hypersensitivity in mice by inducing the integrated stress response (ISR), which is characterized by phosphorylation of eukaryotic initiation factor 2α (p-eIF2α).
Muhammad Saad Yousuf, Marisol Mancilla Moreno, Jiahe Li, Lucy He, Danielle Royer, Jennifer Zhang, Brodie J Woodall, Peter M Grace, Theodore J Price   +8 more
openaire   +2 more sources

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

Frontiers in Immunology
BackgroundThere is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.MethodsIn this ...
Ryan Curtin, Ryan Curtin, Ryan Curtin, Yogambigai Velmurugu, Yogambigai Velmurugu, Yogambigai Velmurugu, Fatoumatta Dibba, Fatoumatta Dibba, Fatoumatta Dibba, Yuan Hao, Samantha Nyovanie, Samantha Nyovanie, Samantha Nyovanie, Andrea Lopez, Andrea Lopez, David Mieles, David Mieles, Courtney Ng, Courtney Ng, Courtney Ng, Katherine Perdomo, Nicole Scott, James B. Lewin, Robin L. Avila, Jen Smrtka, Yury Patskovsky, Yury Patskovsky, Yury Patskovsky, Jonathan Howard, Jonathan Howard, Gregg J. Silverman, Michelle Krogsgaard, Michelle Krogsgaard, Michelle Krogsgaard   +33 more
doaj   +1 more source

Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review

Clinical and Translational Science, Volume 17, Issue 5, May 2024.
Abstract No systematic review of trial designs in patients with relapsing multiple sclerosis (RMS) was reported. This systematic review was conducted on the trial designs and primary end points (PEs) of phase II and III trials intended to modify the natural course of the disease in patients with RMS. The purpose of the study is to explore trends/topics
Katsutoshi Hiramatsu, Hideki Maeda
wiley   +1 more source

The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis

Journal of Immunology Research, Volume 2024, Issue 1, 2024.
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease characterized by the destruction of the myelin sheath of the neuronal axon in the central nervous system. Many risk factors, including environmental, epigenetic, genetic, and lifestyle factors, are responsible for the development of MS.
Sujan Kumar Sarkar, Annie M. L. Willson, Margaret A. Jordan, Roberta Antonia Diotti   +3 more
wiley   +1 more source

Herpes zoster admissions: The majority of patients are not immunised

JEADV Clinical Practice, Volume 4, Issue 1, Page 314-315, March 2025.
Mina Raahimi, Martin Hartmann
wiley   +1 more source

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis

, 2023
International audienceBackground: Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability after onset ...
Filippini, Graziella, Castellini, Greta, Tramacere, Irene, Lucenteforte, Ersilia, Gonzalez-Lorenzo, Marién, Frau, Serena, Perduca, Vittorio, Virgili, Gianni, Benedetti, Maria Donata, Capobussi, Matteo, Featherstone, Robin M.   +10 more
core   +1 more source